Critical role for osteopontin in diabetic nephropathy

Kidney International

Volumn 77, Issue 7, 2010, Pages 588-600

  Nicholas, Susanne B ^a   Liu, Joey ^b   Kim, Jason ^a   Ren, Yuelan ^b   Collins, Alan R ^b   Nguyen, Lam ^a   Hsueh, Willa A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Adhesion molecule; Diabetic nephropathy; Extracellular matrix

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; ANGIOTENSIN II; COLLAGEN TYPE 4; CREATININE; FIBRONECTIN; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOPONTIN; PIOGLITAZONE; ROSIGLITAZONE; STREPTOZOCIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; GENE DELETION; GLOMERULAR DYSFUNCTION; GLUCOSE BLOOD LEVEL; MESANGIUM CELL; MICROALBUMINURIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

ALBUMINURIA; ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; COLLAGEN TYPE IV; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBRONECTINS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY GLOMERULUS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPONTIN; PPAR GAMMA; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA;

EID: 77949540507     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.518     Document Type: Article

References (61)

1. Imano E, Kanda T, Nakatani Y et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 1998; 21: 2135-2139.
2. Isshiki K, Haneda M, Koya D et al. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 2000; 49: 1022-1032.
3. Nicholas SB, Kawano Y, Wakino S et al. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension 2001; 37: 722-727.
4. Tanimoto M, Fan Q, Gohda T et al. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 2004; 53: 1473-1479.
5. Endlich N, Sunohara M, Nietfeld W et al. Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J 2002; 16: 1850-1852.
6. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003; 14: S300-S304.
7. Giachelli CM, Liaw L, Murry CE et al. Osteopontin expression in cardiovascular diseases. Ann NY Acad Sci 1995; 760: 109-126.
8. Sodhi CP, Batlle D, Sahai A. Osteopontin mediates hypoxia-induced proliferation of cultured mesangial cells: role of PKC and p38 MAPK. Kidney Int 2000; 58: 691-700.
9. Susztak K, Bottinger E, Novetsky A et al. Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 2004; 53: 784-794.
10. Oyama Y, Akuzawa N, Nagai R et al. PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. Circ Res 2002; 90: 348-355.
11. Oyama Y, Kurabayashi M, Akuzawa N et al. Troglitazone, a PPARgamma ligand, inhibits osteopontin gene expression in human monocytes/ macrophage THP-1 cells. J Atheroscler Thromb 2000; 7: 77-82.
12. Breyer MD, Bottinger E, Brosius III FC et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005; 16: 27-45.
13. Johnson GL, Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta 2007; 1773: 1341-1348.
14. Lee YJ, Park SJ, Lee WK et al. MG63 osteoblastic cell adhesion to the hydrophobic surface precoated with recombinant osteopontin fragments. Biomaterials 2003; 24: 1059-1066.
15. Breyer MD, Bottinger E, Brosius FC et al. Diabetic nephropathy: of mice and men. Adv Chronic Kidney Dis 2005; 12: 128-145.
16. Bakris GL, Ruilope LM, McMorn SO et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006; 24: 2047-2055.
17. Hsueh WA, Nicholas SB. Peroxisome proliferator-activated receptor-gamma in the renal mesangium. Curr Opin Nephrol Hypertens 2002; 11: 191-195.
18. Sarafidis PA, Lasaridis AN, Nilsson PM et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005; 18: 227-234.
19. Onozaki A, Midorikawa S, Sanada H et al. Rapid change of glucose concentration promotes mesangial cell proliferation via VEGF: inhibitory effects of thiazolidinedione. Biochem Biophys Res Commun 2004; 317: 24-29.
20. Weigert C, Brodbeck K, Bierhaus A et al. c-Fos-driven transcriptional activation of transforming growth factor beta-1: inhibition of high glucose-induced promoter activity by thiazolidinediones. Biochem Biophys Res Commun 2003; 304: 301-307.
21. Mori S, Takemoto M, Yokote K et al. Hyperglycemia-induced alteration of vascular smooth muscle phenotype. J Diabetes Complications 2002; 16: 65-68.
22. Sodhi CP, Phadke SA, Batlle D et al. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: role of osteopontin. Am J Physiol Renal Physiol 2001; 280: F667-F674.
23. Hunter GK, Hauschka PV, Poole AR et al. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J 1996; 317(Part 1): 59-64.
24. Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 1994; 300(Part 3): 723-728.
25. Prince CW, Oosawa T, Butler WT et al. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem 1987; 262: 2900-2907.
26. Higashibata Y, Sakuma T, Kawahata H et al. Identification of promoter regions involved in cell-and developmental stage-specific osteopontin expression in bone, kidney, placenta, and mammary gland: an analysis of transgenic mice. J Bone Miner Res 2004; 19: 78-88.
27. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001; 1552: 61-85.
28. Canfield AE, Farrington C, Dziobon MD et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J Pathol 2002; 196: 228-234.
29. Yokosaki Y, Tanaka K, Higashikawa F et al. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Matrix Biol 2005; 24: 418-427.
30. Beshensky AM, Wesson JA, Worcester EM et al. Effects of urinary macromolecules on hydroxyapatite crystal formation. J Am Soc Nephrol 2001; 12: 2108-2116.
31. Wesson JA, Ganne V, Beshensky AM et al. Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers. Urol Res 2005; 33: 206-212.
32. Wesson JA, Johnson RJ, Mazzali M et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 2003; 14: 139-147.
33. Junaid A, Amara FM. Osteopontin: correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells. Histopathology 2004; 44: 136-146.
34. Kramer AB, Ricardo SD, Kelly DJ et al. Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis. J Pathol 2005; 207: 483-492.
35. Ziyadeh FN, Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int 1991; 39: 464-475.
36. Pistrosch F, Herbrig K, Kindel B et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54: 2206-2211.
37. Kanjanabuch T, Ma LJ, Chen J et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int 2007; 71: 1232-1239.
38. Gassler N, Elger M, Kranzlin B et al. Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat. Kidney Int 2001; 60: 106-116.
39. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147.
40. Wharram BL, Goyal M, Wiggins JE et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16: 2941-2952.
41. Roth M, Black JL. Transcription factors in asthma: are transcription factors a new target for asthma therapy? Curr Drug Targets 2006; 7: 589-595.
42. Pascual G, Fong AL, Ogawa S et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005; 437: 759-763.
43. Bidder M, Shao JS, Charlton-Kachigian N et al. Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J Biol Chem 2002; 277: 44485-44496.
44. Renault MA, Jalvy S, Belloc I et al. AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells. Circ Res 2003; 93: 674-681.
45. Sakata R, Minami S, Sowa Y et al. Trichostatin A activates the osteopontin gene promoter through AP1 site. Biochem Biophys Res Commun 2004; 315: 959-963.
46. Brosius III FC. Trophic factors and cytokines in early diabetic glomerulopathy. Exp Diabesity Res 2003; 4: 225-233.
47. Nerurkar SS, Olzinski AR, Frazier KS et al. P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1. Biomarkers 2007; 12: 87-112.
48. Ophascharoensuk V, Giachelli CM, Gordon K et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999; 56: 571-580.
49. Mazzali M, Hughes J, Dantas M et al. Effects of cyclosporine in osteopontin null mice. Kidney Int 2002; 62: 78-85.
50. Chow FY, Nikolic-Paterson DJ, Ma FY et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007; 50: 471-480.
51. Chow FY, Nikolic-Paterson DJ, Ozols E et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006; 69: 73-80.
52. Kato S, Luyckx VA, Ots M et al. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999; 56: 1037-1048.
53. Collins AR, Schnee J, Wang W et al. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol 2004; 43: 1698-1705.
54. Neves MF, Amiri F, Virdis A et al. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol 2005; 83: 999-1006.
55. Sun Y, Zhang J, Lu L et al. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 2004; 143: 41-51.
56. Eng E, Floege J, Young BA et al. Is mesangial cell proliferation required for extracellular matrix expansion in glomerular disease? Contrib Nephrol 1994; 107: 156-162.
57. Young BA, Johnson RJ, Alpers CE et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995; 47: 935-944.
58. Brennan BJ, Martin NE. Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease. J Am Pharm Assoc (2003) 2004; 44: 604-610; quiz 610-1601
59. Bruemmer D, Collins AR, Noh G et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003; 112: 1318-1331.
60. Liaw L, Birk DE, Ballas CB et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998; 101: 1468-1478.
61. Potier M, L'Azou B, Cambar J. Isolated glomeruli and cultured mesangial cells as in vitro models to study immunosuppressive agents. Cell Biol Toxicol 1996; 12: 263-270.